ENOB Share Price | Renovaro, Inc. Stock Analysis & Recommendation

Q: What does Renovaro, Inc. do?

Overview: Renovaro, Inc. is a biotechnology company focused on developing vaccines for colorectal cancer and gene therapies for HIV/AIDS, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: - Most recent Net Sales: Not available - Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) - Market-cap: USD 61.88 Million (Micro Cap) Key Metrics: - P/E: NA (Loss Making) - Industry P/E: NA - Dividend Yield: 0.00% - Debt Equity: 0.06 - Return on Equity: -24.90% - Price to Book: 0.70 Contact Details: - Address: Century City Medical Plaza, 2080 Century City East LOS ANGELES CA : 90067 - Tel: 1 212 7630184 - Fax: 1 845 8183588 - Website: https://enochianbio.com/

Q: Is Renovaro, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Renovaro, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include the daily moving averages and the weekly Dow Theory, both indicating bearish trends. The weekly RSI is also bearish, while the Bollinger Bands show a bearish signal on both weekly and monthly time frames. Despite some mildly bullish signals in the MACD and KST on the weekly, the overall sentiment remains negative. Additionally, Renovaro's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -80.65% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

81.49 k

Shareholding (Sep 2025)

FII

0.79%

Held by 31 FIIs

DII

95.02%

Held by 4 DIIs

Promoter

0.01%

How big is Renovaro, Inc.?

22-Jun-2025

As of Jun 18, Renovaro, Inc. has a market capitalization of 61.88 million and reported net sales of 0.00 million with a net profit of -74.78 million for the latest four quarters. As of Jun 24, shareholder's funds are at 131.98 million and total assets at 163.13 million.

View full answer

What does Renovaro, Inc. do?

22-Jun-2025

Renovaro, Inc. is a biotechnology company focused on developing vaccines for colorectal cancer and gene therapies for HIV/AIDS, classified as a micro-cap with a market cap of $61.88 million. It currently reports no net sales or profits and has a debt equity ratio of 0.06.

View full answer

Who are in the management team of Renovaro, Inc.?

22-Jun-2025

As of March 2022, the management team of Renovaro, Inc. includes Mr. Rene Sindlev (Independent Chairman), Dr. Mark Dybul (Executive Vice Chairman and Principal Executive Officer), Mr. Henrik Gronfeldt-Sorensen, Mr. Gregg Alton, Dr. Carol Brosgart, and Ms. Evelyn D'An (all Independent Directors). They oversee the company's strategic direction and operations.

View full answer

Is Renovaro, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Renovaro, Inc. is in a bearish trend with weak strength, indicated by negative signals from moving averages, RSI, and Bollinger Bands, while significantly underperforming the S&P 500 with a year-to-date return of -80.65%.

View full answer

Compare Renovaro, Inc. with Similar Stocks

MaxCyte, Inc.bluebird bio, Inc.Aura Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 19 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.14

Return on Equity

29.56%

Price to Book

-1.49

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.47%

6 Months

-60.55%

1 Year

-56.58%

2 Years

-11.7%

3 Years

-82.89%

4 Years

-85.26%

5 Years

-84.74%

Renovaro, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-26.02%

EBIT to Interest (avg)

-19.64

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.06

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.80%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.60

EV to EBIT

-2.92

EV to EBITDA

-2.94

EV to Capital Employed

0.62

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-21.33%

ROE (Latest)

-24.90%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 17 Schemes (4.18%)

Foreign Institutions

Held by 31 Foreign Institutions (0.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 100.34% vs -1,272.09% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-8.70",
          "chgp": "52.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.50",
          "val2": "-49.90",
          "chgp": "109.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.20",
          "val2": "-59.00",
          "chgp": "100.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is -122.67% vs 64.99% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.30",
          "val2": "-19.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.60",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-58.60",
          "val2": "-19.40",
          "chgp": "-202.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.40",
          "val2": "-39.70",
          "chgp": "-122.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.10

-8.70

52.87%

Interest

0.20

0.30

-33.33%

Exceptional Items

4.50

-49.90

109.02%

Consolidate Net Profit

0.20

-59.00

100.34%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 100.34% vs -1,272.09% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-27.30

-19.50

-40.00%

Interest

1.00

0.60

66.67%

Exceptional Items

-58.60

-19.40

-202.06%

Consolidate Net Profit

-88.40

-39.70

-122.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is -122.67% vs 64.99% in Jun 2023

All Annual Results

Company CV

About Renovaro, Inc.

Renovaro, Inc.

Pharmaceuticals & Biotechnology

Enochian Biosciences Inc, formerly DanDrit Biotech USA, Inc., is a Denmark-based biotechnology company. The Company focuses on developing vaccine against colorectal cancer. It has developed various vaccines that are used in various clinical trials in Europe and Asia, including MelCancerVac (MCV) for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark), and Melvaccine (MV), a melanoma cell lysate used as standalone vaccine (pre-clinical state in Denmark). The Company offers MCV platform technology, which is a cellular immunotherapy for treatment of cancer. Also, the Company develops gene therapies for patients with human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS).

Company Coordinates

Company Details

Century City Medical Plaza, 2080 Century City East LOS ANGELES CA : 90067

Tel: 1 212 7630184

https://enochianbio.com/

Registrar Details

Renovaro, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Renovaro, Inc.?

Watch in Real-Time

What does Renovaro, Inc. do?

Who are in the management team of Renovaro, Inc.?

Is Renovaro, Inc. technically bullish or bearish?

Compare Renovaro, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Annual Results Snapshot (Consolidated) - Jun'24

About Renovaro, Inc.

Company Coordinates